Show simple item record

dc.contributor.authorKessler, Uteeng
dc.contributor.authorVaaler, Arne E.eng
dc.contributor.authorSchøyen, Helle Kristineeng
dc.contributor.authorØdegaard, Ketil Joachimeng
dc.contributor.authorBergsholm, Pereng
dc.contributor.authorAndreassen, Ole Andreaseng
dc.contributor.authorMalt, Ulrik F.eng
dc.contributor.authorMorken, Gunnareng
dc.date.accessioned2011-04-28T08:47:45Z
dc.date.available2011-04-28T08:47:45Z
dc.date.issued2010-02-23eng
dc.identifier.citationBMC Psychiatry 10:16en_US
dc.identifier.issn1471-244Xeng
dc.identifier.urihttp://hdl.handle.net/1956/4707
dc.description.abstractBackground The treatment of depressive phases of bipolar disorder is challenging. The effects of the commonly used antidepressants in bipolar depression are questionable. Electroconvulsive therapy is generally considered to be the most effective treatment even if there are no randomized controlled trials of electroconvulsive therapy in bipolar depression. The safety of electroconvulsive therapy is well documented, but there are some controversies as to the cognitive side effects. The aim of this study is to compare the effects and side effects of electroconvulsive therapy to pharmacological treatment in treatment resistant bipolar depression. Cognitive changes and quality of life during the treatment will be assessed. Methods/Design A prospective, randomised controlled, multi-centre six- week acute treatment trial with seven clinical assessments. Follow up visit at 26 weeks or until remission (max 52 weeks). A neuropsychological test battery designed to be sensitive to changes in cognitive function will be used. Setting: Nine study centres across Norway, all acute psychiatric departments. Sample: n = 132 patients, aged 18 and over, who fulfil criteria for treatment resistant depression in bipolar disorder, Montgomery Åsberg Depression Rating Scale Score of at least 25 at baseline. Intervention: Intervention group: 3 sessions per week for up to 6 weeks, total up to 18 sessions. Control group: algorithm-based pharmacological treatment as usual. Discussion This study is the first randomized controlled trial that aims to investigate whether electroconvulsive therapy is better than pharmacological treatment as usual in treatment resistant bipolar depression. Possible long lasting cognitive side effects will be evaluated. The study is investigator initiated, without support from industry.en_US
dc.language.isoengeng
dc.publisherBioMed Centraleng
dc.rightsAttribution CC BYeng
dc.rights.urihttp://creativecommons.org/licenses/by/2.0eng
dc.titleThe study protocol of the Norwegian randomized controlled trial of electroconvulsive therapy in treatment resistant depression in bipolar disordereng
dc.typePeer reviewedeng
dc.typeJournal articleeng
dc.rights.holderCopyright 2010 Kessler et al; licensee BioMed Central Ltd.
dc.rights.holderKessler et al.eng
dc.type.versionpublishedVersioneng
bora.peerreviewedPeer reviewedeng
bora.cristinID349680eng
bibo.doihttp://dx.doi.org/10.1186/1471-244X-10-16eng
dc.identifier.cristinID349680eng
dc.identifier.doihttp://dx.doi.org/10.1186/1471-244X-10-16


Files in this item

Thumbnail
Thumbnail
Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution CC BY
Except where otherwise noted, this item's license is described as Attribution CC BY